FDA Clears First Nebulized LAMA Inhaler for COPD FDA Clears First Nebulized LAMA Inhaler for COPD
Glycopyrrolate inhalation solution 25 mcg twice daily (Lonhala Magnair) is for maintenance treatment of airflow obstruction in adults with chronic obstructive pulmonary disease (COPD).FDA Approvals
CONCLUSIONS: Specialists had diverse perceptions and clinical practices regarding severe asthma and ACOS patients. This heterogeneity must be considered in future studies and strategy development for severe asthma and ACOS. PMID: 29676069 [PubMed]
Authors: Kapellos TS, Bassler K, Aschenbrenner AC, Fujii W, Schultze JL Abstract Chronic obstructive pulmonary disease (COPD) is a diverse respiratory disease characterised by bronchiolitis, small airway obstruction, and emphysema. Innate immune cells play a pivotal role in the disease's progression, and in particular, lung macrophages exploit their prevalence and strategic localisation to orchestrate immune responses. To date, alveolar and interstitial resident macrophages as well as blood monocytes have been described in the lungs of patients with COPD contributing to disease pathology by changes in their functio...
This study aimed to characterize patients initiating treatment with the LAMA tiotropium (TIO) and the fixed-dose LAMA/LABA combination therapy umeclidinium/vilanterol (UMEC/VI), and to compare rates of escalation to TT between patients receiving these therapies.
Before her passing earlier this week, former First Lady Barbara Bush announced that she would be spending her final days at home with her family utilizing “comfort care” in lieu of continued medical treatment for her congestive heart failure and COPD. She chose quality of life over quantity of life.
Objective. We evaluated the relationship between various risk scores (SYNTAX score (SS), SYNTAX score-II (SS-II), thrombolysis in myocardial infarction (TIMI) risk scores and Global Registry of Acute Coronary Events (GRACE) risk scores) and major adverse cardiovascular events (MACE) in non-ST-elevation myocardial infarction (NSTEMI) patients undergoing percutaneous coronary intervention (PCI). Subjects and Methods: The study population were selected from among 589 patients who underwent coronary angiography with a diagnosis of NSTEMI. TIMI and GRACE risk scores were calculated. SS and SS-II were calculated in all patients,...
CONCLUSIONS: Heightened NK cytotoxicity against lung epithelial cells in COPD results primarily from lung DC-mediated priming via IL-15 trans-presentation on IL-15Rα. Future studies are required to test whether increased NK cytotoxicity contributes to COPD pathogenesis. PMID: 29676596 [PubMed - as supplied by publisher]
Publication date: 21–27 April 2018 Source:The Lancet, Volume 391, Issue 10130 Author(s): The Lancet
Annals of the American Thoracic Society,Volume 15, Issue Supplement_2, Page S122-S123, April 2018.
Annals of the American Thoracic Society,Volume 15, Issue Supplement_2, Page S132-S132, April 2018.
Several inhaled drugs are dependent on organic cation transporters to cross cell membranes. To further evaluate their potential to impact on inhaled drug disposition, the localization of MATE1, P-gp, OCTN1 and...